PHGUF
Price
$1.15
Change
-$0.00 (-0.00%)
Updated
Jun 26 closing price
Capitalization
696.5M
XFOR
Price
$1.82
Change
-$0.01 (-0.55%)
Updated
Jul 25 closing price
Capitalization
13.07M
4 days until earnings call
Interact to see
Advertisement

PHGUF vs XFOR

Header iconPHGUF vs XFOR Comparison
Open Charts PHGUF vs XFORBanner chart's image
Pharming Group
Price$1.15
Change-$0.00 (-0.00%)
Volume$100
Capitalization696.5M
X4 Pharmaceuticals
Price$1.82
Change-$0.01 (-0.55%)
Volume$1.55M
Capitalization13.07M
PHGUF vs XFOR Comparison Chart in %
Loading...
PHGUF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XFOR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PHGUF vs. XFOR commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PHGUF is a Hold and XFOR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (PHGUF: $1.15 vs. XFOR: $1.82)
Brand notoriety: PHGUF and XFOR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PHGUF: 30% vs. XFOR: 170%
Market capitalization -- PHGUF: $696.5M vs. XFOR: $13.07M
PHGUF [@Biotechnology] is valued at $696.5M. XFOR’s [@Biotechnology] market capitalization is $13.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PHGUF’s FA Score shows that 1 FA rating(s) are green whileXFOR’s FA Score has 2 green FA rating(s).

  • PHGUF’s FA Score: 1 green, 4 red.
  • XFOR’s FA Score: 2 green, 3 red.
According to our system of comparison, both PHGUF and XFOR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PHGUF’s TA Score shows that 3 TA indicator(s) are bullish while XFOR’s TA Score has 5 bullish TA indicator(s).

  • PHGUF’s TA Score: 3 bullish, 1 bearish.
  • XFOR’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, XFOR is a better buy in the short-term than PHGUF.

Price Growth

PHGUF (@Biotechnology) experienced а 0.00% price change this week, while XFOR (@Biotechnology) price change was +27.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.62%. For the same industry, the average monthly price growth was +17.39%, and the average quarterly price growth was +28.36%.

Reported Earning Dates

XFOR is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHGUF($696M) has a higher market cap than XFOR($13.1M). PHGUF YTD gains are higher at: 17.168 vs. XFOR (-91.730). XFOR has higher annual earnings (EBITDA): 25.2M vs. PHGUF (21.4M). PHGUF has more cash in the bank: 107M vs. XFOR (87M). XFOR has less debt than PHGUF: XFOR (78M) vs PHGUF (119M). PHGUF has higher revenues than XFOR: PHGUF (321M) vs XFOR (31.4M).
PHGUFXFORPHGUF / XFOR
Capitalization696M13.1M5,313%
EBITDA21.4M25.2M85%
Gain YTD17.168-91.730-19%
P/E RatioN/A0.86-
Revenue321M31.4M1,022%
Total Cash107M87M123%
Total Debt119M78M153%
FUNDAMENTALS RATINGS
PHGUF vs XFOR: Fundamental Ratings
PHGUF
XFOR
OUTLOOK RATING
1..100
3834
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
15
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9112
PRICE GROWTH RATING
1..100
4497
P/E GROWTH RATING
1..100
13100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XFOR's Valuation (15) in the Biotechnology industry is somewhat better than the same rating for PHGUF (78) in the null industry. This means that XFOR’s stock grew somewhat faster than PHGUF’s over the last 12 months.

XFOR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PHGUF (100) in the null industry. This means that XFOR’s stock grew similarly to PHGUF’s over the last 12 months.

XFOR's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for PHGUF (91) in the null industry. This means that XFOR’s stock grew significantly faster than PHGUF’s over the last 12 months.

PHGUF's Price Growth Rating (44) in the null industry is somewhat better than the same rating for XFOR (97) in the Biotechnology industry. This means that PHGUF’s stock grew somewhat faster than XFOR’s over the last 12 months.

PHGUF's P/E Growth Rating (13) in the null industry is significantly better than the same rating for XFOR (100) in the Biotechnology industry. This means that PHGUF’s stock grew significantly faster than XFOR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PHGUFXFOR
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
40%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
36%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 3 days ago
64%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
41%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
40%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
N/A
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
52%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
PHGUF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XFOR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SLE5.120.02
+0.39%
Super League Enterprise Inc
LDOS163.25N/A
N/A
Leidos Holdings
AROC23.30-0.07
-0.30%
Archrock
MNSB21.16-0.14
-0.66%
MainStreet Bancshares
TMP64.25-0.84
-1.29%
Tompkins Financial Corp

PHGUF and

Correlation & Price change

A.I.dvisor tells us that PHGUF and DRUG have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PHGUF and DRUG's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHGUF
1D Price
Change %
PHGUF100%
N/A
DRUG - PHGUF
28%
Poorly correlated
+10.83%
CGTX - PHGUF
25%
Poorly correlated
-2.51%
IMMP - PHGUF
23%
Poorly correlated
+1.18%
XFOR - PHGUF
23%
Poorly correlated
-0.55%
TVGN - PHGUF
22%
Poorly correlated
-0.93%
More